Currently, immune checkpoint inhibitors, such as anti-PD-L1 and anti-CTLA-4 antibodies, elicit durable responses in some solid tumours, including ATCs [13–16]. The gene discussed is CD274; the disease is Ehlers-Danlos syndrome, musculocontractural type.